Castle Biosciences is a startup based in the United States, most recent round Series-c-plus, 1 tracked investor.
Based in the United States, Castle Biosciences is a startup. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
Castle Biosciences develops and commercializes genomic and proteomic diagnostic tests that provide risk stratification and clinical decision support for patients with skin cancers and other malignancies. Their commercially available assays (e.g., DecisionDx tests) are used by clinicians to inform prognosis and treatment planning.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.